SYRS stock reflects a 2025 Nasdaq delisting and wind down

Syros Pharmaceuticals (ISIN US8719201096) approved a voluntary Nasdaq delisting on February 28, 2025, after its lead Phase 3 trial failed to meet its primary endpoint, according to EdgeChat AI. The development placed SYRS stock in the context of a creditor-approved wind down rather than an active Nasdaq growth story.

Delisting followed trial failure

The SELECT-MDS-1 study evaluated tamibarotene with azacitidine in patients with higher-risk myelodysplastic syndrome. The trial failed its primary endpoint of complete response rate, and the result triggered an event of default under Syros's loan and security agreement with Oxford Finance, according to EdgeChat AI.

Syros then planned to file a Form 25 around March 10, 2025, followed by a Form 15 around March 20, 2025. The company agreed to limit spending to a budget approved by Oxford Finance, marking a sharp change from its earlier clinical-development strategy.

Historical revenue shows the scale

Syros reported revenue of USD 9.9 million in fiscal year 2023, compared with USD 2.0 million in fiscal year 2019, a compound annual increase of 49.6 percent, according to Fair Value Calculator. The same historical record shows a net loss of USD 165.0 million in fiscal year 2023, underscoring the gap between licensing-related revenue and sustainable profitability.

The business model centered on small molecules designed to control gene expression in cancer and monogenic diseases. Syros's investor-relations page describes its mission as developing new standards of care for frontline treatment of hematologic malignancies, while its pipeline historically included tamibarotene, SY-2101 and SY-5609.

SYRS stock remains an OTC security

MarketWatch identified SYRS as a US OTC security and showed a last quoted price of USD 0.0004 on September 11, 2026, with 62,234 shares traded that day. The historical quote places the security far below the operating scale implied by its fiscal year 2023 revenue, but it does not establish an active Nasdaq listing.

For investors reviewing the symbol, the decisive facts are the February 2025 delisting, the clinical setback and the wind-down structure. Syros Pharmaceuticals remains classified in biotechnology, with its historical profile centered on hematologic malignancies and gene-expression therapies.

More news and analysis on SYRS stock